These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 6850647)

  • 21. [Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine after intraperitoneal administration].
    Noda T; Oku M; Kiyozuka Y; Maruyama M; Adachi S; Akada S; Okamura Y; Ichijo M
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2929-35. PubMed ID: 3178241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular distribution of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in blood cells.
    Ueda T; Nakamura T; Kagawa D; Yamamoto K; Uchida M; Sasada M; Uchino H
    Gan; 1983 Jun; 74(3):445-51. PubMed ID: 6884702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo distribution of 14C-labeled N4-behenoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Toyoshima S; Fukuma M; Seto Y; Fujita H; Fukushima K; Tomioka H; Sakurai T; Sugimoto Y; Yagi T; Hoshino T; Sowa T
    Gan; 1981 Feb; 72(1):19-29. PubMed ID: 7274645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
    Nakamura T; Ueda T
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Hug V; Keating MJ; Chubb S
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Paul CY; Gahrton CG; Peterson CO
    Cancer Res; 1985 May; 45(5):2373-5. PubMed ID: 3986778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Ohno R; Amaki I; Hattori K; Hirota Y; Hoshino A; Ichimaru M; Ito M; Kimura I; Maekawa T
    Med Oncol Tumor Pharmacother; 1986; 3(1):15-24. PubMed ID: 3702507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
    Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
    Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
    Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
    Kreis W; Chaudhri F; Chan K; Allen S; Budman DR; Schulman P; Weiselberg L; Freeman J; Deere M; Vinciguerra V
    Cancer Res; 1985 Dec; 45(12 Pt 1):6498-501. PubMed ID: 3864533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chemotherapeutic effects in hypoplastic leukemia].
    Takahashi I; Nakada H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1209-14. PubMed ID: 3260089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
    Yoshida T; Kobayashi K; Nakamura S; Ohtake S; Itoh K; Kanno M; Hirai J; Yasushi ; Matsuda TT
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):625-30. PubMed ID: 3162669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
    Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
    J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.